CRISPR Therapeutics director granted 13K options
CRISPR Therapeutics AG reported that director Sandesh Mahatme received a grant of stock options covering 13,000 common shares.
Rhea-AI Filing Summary
CRISPR Therapeutics AG reported that director Sandesh Mahatme received a grant of stock options covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the terms, the award vests in 12 equal monthly installments, subject to continued service, with the first installment vesting on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting. This is a compensation-related award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 13,000 shares
Grant/Award
1 txn
Insider
Mahatme Sandesh
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct)
Footnotes (1)
- F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Key Figures
Stock options granted: 13,000 options
Exercise price: $51.84 per share
Expiration date: June 5, 2036
+2 more
5 metrics
Stock options granted
13,000 options
Award of stock options to director Sandesh Mahatme; total options held after grant
Exercise price
$51.84 per share
Exercise price for the granted stock options
Expiration date
June 5, 2036
Final date by which options must be exercised
Vesting structure
12 monthly installments
Vests from June 30, 2026 to earlier of one-year anniversary or 2027 Annual Meeting
Underlying shares
13,000 common shares
Number of CRISPR Therapeutics common shares subject to the options
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "51.8400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"the options will vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting financial
"last installment vests on the earlier of ... the 2027 Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRISPR Therapeutics (CRSP) report for Sandesh Mahatme?
CRISPR Therapeutics reported that director Sandesh Mahatme received a grant of stock options for 13,000 common shares. These options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.
How many CRISPR Therapeutics (CRSP) stock options were granted and at what price?
Sandesh Mahatme was granted 13,000 stock options with an exercise price of $51.84 per share. This price is the cost to acquire each common share if he chooses to exercise the options before they expire in 2036, subject to vesting.
When do Sandesh Mahatme’s CRISPR Therapeutics (CRSP) options vest?
The options vest in 12 equal monthly installments, starting on June 30, 2026. Vesting continues monthly, with the final installment vesting on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting, assuming continued service.
When do the granted CRISPR Therapeutics (CRSP) stock options expire?
The granted stock options expire on June 5, 2036, if not exercised by that date. After expiration, the right to purchase CRISPR Therapeutics common shares at the $51.84 exercise price lapses, so value depends on exercising within the term once vested.
Is this CRISPR Therapeutics (CRSP) Form 4 an open-market buy or sell?
This Form 4 reflects a grant of 13,000 stock options as compensation, not an open-market buy or sell. The transaction is coded as an acquisition award, giving future purchase rights rather than documenting immediate trading in CRISPR Therapeutics common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
